English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Valeant to Sell Dendreon to the Sanpower Group For $819.9 Million

Jan. 9, 2017

Valeant Pharmaceuticals International, Inc. has announced that its affiliate entered into a definitive agreement to sell all of the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the Sanpower Group Co. Ltd., one of the largest privately owned conglomerates in China. Under the terms of the transaction, Valeant will receive a cash consideration of $819.9 million at completion.

Dendreon's first and only commercialized product is Provenge®, an autologous cellular immunotherapy (vaccine) for prostate cancer treatment approved by the FDA in April 2010.